Patents by Inventor Yeming Wang

Yeming Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
    Patent number: 11919918
    Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: March 5, 2024
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Gong Li, Xiang Li, Yuanyuan Jiang, Kai Liu, Yeming Wang, Liying Zhou, Yanan Liu, Ning Shao, Fengping Xiao
  • Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof
    Patent number: 11905274
    Abstract: The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: February 20, 2024
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Gong Li, Xiang Li, Yuanyuan Jiang, Yeming Wang, Huai Huang, Liying Zhou, Yanan Liu, Ning Shao, Fengping Xiao, Zhenguang Zou
  • COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE
    Publication number: 20230159559
    Abstract: Provided is an EGFR kinase inhibitor according to general formula (I) and a pharmaceutical composition containing the inhibitor. The invention can be used to treat diseases related to EGFR kinase, such as cancer. Also provided is a preparation and use of the above inhibitor.
    Type: Application
    Filed: December 16, 2020
    Publication date: May 25, 2023
    Inventors: Yanping Zhao, Hongjun Wang, Yeming Wang, Yuanyuan Jiang, Futian Fan, Huining Liang, Xiaoqian Wang, Yong Xie, Yanhao Zhang, Xuelian Liu
  • RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF
    Publication number: 20230106958
    Abstract: The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.
    Type: Application
    Filed: May 25, 2022
    Publication date: April 6, 2023
    Inventors: Yanping ZHAO, Hongjun WANG, Yeming WANG, Xiang LI, Yuanyuan JIANG, Huai HUANG, Fajie LI, Liying ZHOU, Ning SHAO, Fengping XIAO, Zhenguang ZOU
  • P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF
    Publication number: 20220389039
    Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Application
    Filed: May 27, 2022
    Publication date: December 8, 2022
    Inventors: Yanping ZHAO, Hongjun WANG, Gong LI, Xiang LI, Yuanyuan JIANG, Kai LIU, Yeming WANG, Liying ZHOU, Yanan LIU, Ning SHAO, Fengping XIAO
  • P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
    Publication number: 20220332714
    Abstract: Disclosed are a P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition containing same, and the use thereof for preventing or treating a disease regulated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Application
    Filed: June 5, 2020
    Publication date: October 20, 2022
    Inventors: Yanping ZHAO, Hongjun WANG, Yeming WANG, Liying ZHOU, YANAN LIU
  • COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK
    Publication number: 20220306659
    Abstract: A new compound of general formula (X) inhibiting and inducing degradation of an EGFR and ALK, and a pharmaceutical composition containing said compound. The compound and the pharmaceutical composition can be used for treating diseases related to the EGFR and the ALK kinase, such as cancer. The present invention further provides the preparation and use of the compound.
    Type: Application
    Filed: August 21, 2020
    Publication date: September 29, 2022
    Inventors: Yanping Zhao, Hongjun Wang, Yeming Wang, Futian Fan, Yuanyuan Jiang, Xiaoqian Wang, Huining Liang, Yong Xie, Yanhao Zhang, Kai Liu, Zewang Feng, Xuelian Liu
  • Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
    Patent number: 11453690
    Abstract: The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: September 27, 2022
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Yeming Wang, Xiang Li, Yuanyuan Jiang, Huai Huang, Fajie Li, Liying Zhou, Ning Shao, Fengping Xiao, Zhenguang Zou
  • P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
    Patent number: 11414444
    Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 16, 2022
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Gong Li, Xiang Li, Yuanyuan Jiang, Kai Liu, Yeming Wang, Liying Zhou, Yanan Liu, Ning Shao, Fengping Xiao
  • RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF
    Publication number: 20210395231
    Abstract: The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.
    Type: Application
    Filed: February 22, 2019
    Publication date: December 23, 2021
    Inventors: Yanping ZHAO, Hongjun WANG, Gong LI, Xiang LI, Yuanyuan JIANG, Yeming WANG, Huai HUANG, Liying ZHOU, Yanan LIU, Ning SHAO, Fengping XIAO, Zhenguang ZOU
  • P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF
    Publication number: 20210179648
    Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
    Type: Application
    Filed: October 31, 2018
    Publication date: June 17, 2021
    Inventors: Yanping ZHAO, Hongjun WANG, Gong LI, Xiang LI, Yuanyuan JIANG, Kai LIU, Yeming WANG, Liying ZHOU, Yanan LIU, Ning SHAO, Fengping XIAO
  • RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF
    Publication number: 20210054007
    Abstract: The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.
    Type: Application
    Filed: March 22, 2019
    Publication date: February 25, 2021
    Inventors: Yanping ZHAO, Hongjun WANG, Yeming WANG, Xiang LI, Yuanyuan JIANG, Huai HUANG, Fajie LI, Liying ZHOU, Ning SHAO, Fengping XIAO, Zhenguang ZOU
  • Nanocrystal cerium zirconium composite oxide, its preparation and application
    Patent number: 6605565
    Abstract: A nanocrystal cerium zirconium composite oxide and its preparation and application are disclosed. The nanocrystal cerium zirconium composite oxide of the present invention comprises 4-98% by weight of CeO2 and 1-95% by weight of ZrO2, the crystalline particle size thereof is 100 nm or less, and the ignition loss thereof after igniting at 900° C. for one hour is smaller than 5%.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: August 12, 2003
    Assignees: Shanghai Yue Long Non-Ferrous Metals Ltd., Tong Ji University
    Inventors: Deyuan Zhang, Zhenhua Wang, Shixin Lu, Jieda Wu, Yeming Wang, Yuxiang Yang, Shaogang Wang